Vertex Pharmaceuticals Incorporated today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the ...
Third quarter performance driven by strong portfolio royalty revenue growth of 47%2025 full year revenue guidance increased to $225 million - ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈